Editor-in-Chief
Alan D. T. Barrett, PhD
Director, Sealy Institute for Vaccine Sciences
University of Texas Medical Branch
TX, USA
Alan D.T. Barrett obtained his B.S., M.S. and PhD in the area of virology from the University of Warwick, followed by a post-doctoral fellowship in arbovirology at the London School of Hygiene and Tropical Medicine. He is currently Director of the Sealy Institute for Vaccine Sciences and the World Health Organization Collaborating Center for Vaccine Research, Evaluating and Training for Emerging Infectious Diseases. He is a Professor in the Departments of Pathology and Microbiology & Immunology at University of Texas, Medical Branch (UTMB). Dr. Barrett is a leading expert in the fields of vaccine development for flaviviruses. His lab is undertaking basic research and preclinical development for vaccines against various flavivirus diseases. He has made several contributions to World Health Organization activities on vaccine research, development and implementation. He is a member of the Scientific Advisory Committee, Coalition for Epidemic Preparedness Innovations (CEPI) that is developing vaccines for Ebola, Nipah, Lassa fever and MERS, the flavivirus vaccine working group of the CDC Advisory Committee on Immunization Practices and has served on many NIH study sections.
Associate Editors
Paul A. MacAry, PhD
Director, LSI Immunology Programme
National University of Singapore
Singapore, Singapore
Associate Professor Paul MacAry received his BSc (Hons) in Molecular Genetics from Glasgow University in 1993 and his PhD in Immunology from GKT, University of London in 1998. He performed post-doctoral researches in the Cambridge University Institute for Medical Research (CIMR) and since 2005 has been an independent investigator in the Department of Microbiology and Immunology program at the National University of Singapore (NUS). The multi-disciplinary research in his laboratory covers the entire spectrum of scientific endeavour, from basic research to industrial applications with an emphasis on antibody biology, immune repertoire mapping and protein engineering applications in infectious diseases. Professor MacAry was a founding member and Meetings Secretary for the Singaporean Society of Immunology (SSI) — Singapore’s first international learned society — and the founding scientist for two biotechnology companies, BSCR LTD founded in Cambridge in 2004 and Antibody Cradle LTD founded in Singapore in 2012.
Pei-Yong Shi, PhD
I.H. Kempner Professor of Human Genetics
University of Texas Medical Branch
TX, USA
Along with his post at UTMB, Pei-Yong Shi serves as adjunct Professor of Emerging Infectious Diseases at the Duke-NUS Graduate Medical School in Singapore and Honorary Professor at the Wuhan Institute of Virology, Chinese Academy of Sciences. He studies flaviviruses and develops antivirals and vaccines. He received his PhD from Georgia State University. After postdoctoral training at Yale, he joined Bristol-Myers Squibb to develop antiviral drugs and New York State Department of Health to study emerging viral diseases. From 2008 to 2015, he served as Executive Director to lead drug discovery at Novartis Institute for Tropical Diseases. His group developed the first infectious clones of the epidemic strain of West Nile and Zika viruses, discovered two cap methylation activities of flavivirus NS5 protein, identified essential RNA elements for flavivirus replication, established various platforms for flavivirus vaccine and drug discovery and pioneered therapeutics development for dengue virus.
Richard Titball, DsC, PhD
Professor of Molecular Microbiology
University of Exeter
Exeter, United Kingdom
Prof. Titball has worked extensively on a range of bacterial pathogens including Burkholderia pseudomallei, Francisella tularensis, Yersinia pestis, Campylobacter jejuni and Clostridium perfringens originally at the Defence Science and Technology Laboratory and more recently at the University of Exeter where he is Professor of Molecular Microbiology. His past work has provided new insight into the molecular architectures and mode of action of bacterial toxins and he led initiatives to sequence and exploit the first genomes of a range of candidate biothreat agents. Prof. Titball’s work also resulted in the development of vaccines against plague and C. perfringens toxins which have been trialled in humans and in animals, respectively. His principal interests now lie with understanding the molecular basis of disease caused by B. pseudomallei and C. perfringens and the development of vaccines against disease caused by these pathogens.
Veronika von Messling, Dr. med. vet.
Director General, Life Sciences
Federal Ministry of Education and Research
Berlin, Germany
Prof. Dr. Veronika von Messling is Director General of Life Sciences at the Federal Ministry of Education and Research in Germany. She obtained her veterinary degree and her doctorate degree in veterinary virology from the Veterinary School Hannover, Germany. After postdoctoral training at Mayo Clinic in Rochester, MN, she was an Assistant Professor at INRS-Institut Armand-Frappier in Laval, QC, and then Associate Professor at Duke-NUS Medical School, Singapore. Her research interest lies in characterizing the pathogenesis of respiratory viruses to develop novel prophylactic and therapeutic strategies. Dr. von Messling has been awarded various awards and prizes such as the Chercheur-boursier senior Award, FRSQ, (2011), and the Löffler-Frosch Prize, German Society of Virology (2011). She is also a member of various societies such as the European Society of Virology, Canadian Society of Microbiology and Deutsche virologische Gesellschaft.
David H. Walker, MD, PhD
Department of Pathology
University of Texas Medical Branch
TX, USA
David Walker is the Director of the Center for Biodefense and Emerging Infectious Diseases, and Professor and former Chairman of the Department of Pathology at the University of Texas Medical Branch at Galveston. He received his M.D. from Vanderbilt University, and then later served as a Research and Clinical Fellow at Harvard University School of Medicine. Dr. Walker’s research has elucidated mechanisms of immunity to Rickettsia and Ehrlichia, developed animal models for investigating rickettsioses and ehrlichioses and contributed to elucidating the pathology and pathophysiology of Lassa fever, Rocky Mountain spotted fever, Mediterranean spotted fever and human monocytotropic ehrlichiosis. Among emerging infections, he contributed to the discovery, characterization and/or epidemiology of Anaplasma phagocytophilum (human granulocytotropic anaplasmosis), Rickettsia japonica (Japanese spotted fever), R. felis (flea-borne spotted fever) and E. chaffeensis (human monocytotropic ehrlichiosis).
Editorial Board Members
L. Garry Adams — Texas A&M College Station, Texas, USA
Sylvie Alonso — National University of Singapore, Singapore, Singapore
Carl R. Alving — Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
Peter L. Andersen — Statens Serum Institute, Copenhagen, Denmark
Bernard Arulanandam — University of Texas at San Antonio, Texas, USA
David W. C. Beasley — University of Texas Medical Branch, Texas, USA
Martin Beer — Friedrich-Loeffler-Institut, Greifswald-Insel Riems, Germany
David I. Bernstein — Cincinnati Children's Hospital Medical Center, Ohio, USA
Paul L. Bigliardi — University of Minnesota, Minnesota, USA
Danny Casimiro — Aeras, Maryland, USA
Ashok K. Chopra — University of Texas Medical Branch,Texas, USA
James Crowe — Vanderbilt University, Tennessee, USA
Denise Doolan — James Cook University, Australia
J. Stephen Dumler — Uniformed Services University for the Health Sciences, Maryland, USA
Janice Endsley — University of Texas Medical Branch (UTMB),Texas, USA
Susanna Esposito — Università degli Studi di Milano, Milan, Italy
Ali I. Fattom — NanoBio Corporation, Michigan, USA
Thomas Ficht — Texas A&M University, Texas, USA
Katja Fink — Humabs BioMed SA, Bellinzona, Switzerland
Anthony R. Fooks — Animal and Plant Health Agency (APHA), Surrey, UK
Alexander Freiberg — University of Texas Medical Branch, Texas, USA
Tong-Ming Fu — Merck & Co., Philadelphia, USA
Michael Gale, Jr. — University of Washington, Washington, USA
Adolfo Garcia-Sastre — Mount Sinai School of Medicine New York, USA
Nathalie Garcon — Bioaster Technology Research Institute, Brussels, Belgium
Nisha J. Garg — University of Texas Medical Branch,Texas, USA
Sarah Gilbert — Jenner Institute, University of Oxford, Oxford, UK
Jaap Goudsmit — University of Amsterdam, Amsterdam, Netherlands
Barney S. Graham — NIH, Maryland, USA
Beth-Ann Griswold Coller — Merck Research Laboratories, New Jersey, USA
Joachim Hombach — World Health Organization, Geneva, Switzerland
Tetsuro Ikegami — University of Texas Medical Branch, Texas, USA
Ken J. Ishii — Osaka University, Osaka, Japan
Nicholas Jackson — Sanofi-Pasteur, Lyon, France
Kathrin Jansen — Pfizer Vaccine Research, New York, USA
Stefan Kappe — Seattle Biomedical Research Institute, Washington, USA
David C. Kaslow — PATH, Seattle, Washington, USA
Stephen Kent — University of Melbourne, Melbourne, Australia
Janine Kimpel — Medical University of Innsbruck, Innsbruck, Australia
Dennis M. Klinman — National Cancer Institute, NIH, Maryland, USA
Eiji Konishi — Osaka University, Osaka, Japan
Margaret Liu — Karolinska Institute, Stockholm, Sweden
Shan Lu — University of Massachusetts Medical School, Massachusetts, USA
Mary Marovich — National Institute of Allergy and Infectious Diseases, NIH, Maryland, USA
Peter Mason — Regeneron Pharmaceuticals, Tarrytown, New York, USA
Jere W. McBride — University of Texas Medical Branch,Texas, USA
Philip Minor — National Institute for Biological Standards and Control, Potters Bar, UK
Thomas P. Monath — NewLink Genetics, Iowa, USA
Kathleen M. Neuzil — University of Maryland School of Medicine, Maryland, USA
Walter Orenstein — Emory University, Georgia, USA
Slobodan Paessler — University of Texas Medical Branch, Texas, USA
Guy H. Palmer — Washington State University, Washington, USA
Daniel Paris — Mahidol Oxford Research Unit, Bangkok, Thailand
Kevin Pethe — Nanyang Technological University, Singapore
Stanley Plotkin — University of Pennsylvania, Vaxconsult, Pennsylvania, USA
Maarten Postma — University of Groningen, Groningen, Netherlands
Bali Pulendran — Emory University, Atlanta, Georgia, USA
Cheng-Feng Qin — Beijing Institute of Microbiology and Epidemiology, Beijing, China
Rino Rappuoli — GSK Vaccines, Siena, Italy
Steven G. Reed — Infectious Diseases Research Institute, Washington, USA
Guus Rimmelzwaan — University of Veterinary Medicine, Center for Emerging Infections and Zoonoses, Hanover, Germany
Jai Rudra — Washington University in St. Louis, Missouri, USA
Richard Rupp — University of Texas Medical Branch, Texas, USA
Robert Sauerwein — Radboud University Medical Center, Nijmegen, Netherlands
Alexander Schmidt — GSK Vaccines, Brussels, Belgium
Alessandro Sette — La Jolla Institute for Allergy and Immunology, California, USA
John Shiver — Sanofi-Pasteur Vaccines, Swiftwater, Pennsylvania, USA
Mark K. Slifka — Oregon Health & Science University, Orlando, USA
Jon Smith — PaxVax, Inc., San Diego, CA, USA
Lynn Soong — University of Texas Medical Branch, Texas, USA
J. Erin Staples — Centers for Disease Control, Colorado, USA
Geraldine Taylor — Pirbright Institute, Woking, UK
Dirk Teuwen — Union Chimique Belge (UCB), Brussels, Belgium
Ralph A. Tripp — The UGA college of Veterinary Medicine, Georgia, USA
Takafumi Tsuboi — Ehime University, Ehime, Japan
Sylvia van den Hurk — University of Saskatchewan, Saskatchewan, Canada
Kirsten Vannice — World Health Organization, Geneva, Switzerland
Hengliang Wang — Beijing Institute of Biotechnology, Beijing, China
Scott C. Weaver — University of Texas Medical Branch, Texas, USA
David B. Weiner — University of Pennsylvania, Pennsylvania, USA
Fidel Zavala — John Hopkins Bloomberg School of Public Health, Maryland, USA
Qinjian Zhao — Xiamen University, Xiamen, Fujian, China
京公网安备 11010802027423号